Viewing Study NCT02260661

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 12:58 PM
Ignite Modification Date: 2026-02-08 @ 11:39 AM
Study NCT ID: NCT02260661
Status: COMPLETED
Last Update Posted: 2016-10-10
First Post: 2014-10-06
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours
Sponsor: AstraZeneca
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Advanced Solid Malignancies View
None Breast Cancer - ER+, HER2 - View
None Breast Cancer - ER+, HER2-, PIK3CA Gene Mutation View
Keywords:

Keywords

Keyword Brief Keyword Text View
None AZD8835 View
None Fulvestrant View
None Breast Cancer View
None PIK3CA Gene Mutation View